AtriCure Recognized as a Minnesota Top Workplaces for 6th Consecutive Year
MASON, Ohio—June 22, 2026– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it has been named one of Minnesota’s Top Workplaces for the 6th year in a row. The recognition reflects AtriCure’s ongoing commitment to creating an environment where employees can do meaningful work, grow professionally, and contribute to improving patient outcomes.
This award is based on confidential employee feedback gathered through a third-party survey that measures key drivers of engaged workplace cultures, including alignment, execution, connection, and leadership. Earning this recognition for six years underscores the consistency of AtriCure’s culture and the shared purpose of its teams.
“It’s an honor to be recognized for this award, particularly because it is driven by the voices of our people,” said Mike Carrel, AtriCure President and CEO. “We work to ensure we sustain a workplace where everyone is empowered to bring their passion and collaboration to work on behalf of patients worldwide.”
AtriCure supports its teams through a mission-driven culture focused on innovation, patient impact, and continuous improvement, alongside investments in development, mentorship, and recognition programs. The company continues to grow and welcomes professionals who are energized by advancing standards of care in the treatment of atrial fibrillation and pain after surgery.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications, and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.